{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:25:55Z","timestamp":1790259955836,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,19]]},"DOI":"10.7759\/cureus.69730","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:08:15Z","timestamp":1726747695000},"source":"Crossref","is-referenced-by-count":13,"title":["Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices"],"prefix":"10.7759","author":[{"given":"Ayoyimika O","family":"Okunlola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope O","family":"Ajao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwila","family":"Sabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka  D","family":"Kolawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osasere  A","family":"Eweka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toluwani E","family":"Adebayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082192","article-title":"Criteria and non-criteria antiphospholipid antibodies in antiphospholipid syndrome: how strong are they correlated?","volume":"11","author":"Caraiola S","year":"2023","unstructured":"Caraiola S, Voicu L, Jurcut C, et al.. Criteria and non-criteria antiphospholipid antibodies in antiphospholipid syndrome: how strong are they correlated?. Biomedicines. 2023, 11:10.3390\/biomedicines11082192","journal-title":"Biomedicines"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-009-0073-6","article-title":"Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome","volume":"12","author":"Cervera R","year":"2010","unstructured":"Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010, 12:70-6. 10.1007\/s11926-009-0073-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera R","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Colafrancesco S, et al.. 14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014, 13:699-707. 10.1016\/j.autrev.2014.03.002","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12860\/jnp.2014.02","article-title":"What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: is it time for formulating a classification for renal morphologic lesions?","volume":"3","author":"Mubarak M","year":"2014","unstructured":"Mubarak M, Nasri H. What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: is it time for formulating a classification for renal morphologic lesions?. J Nephropathol. 2014, 3:4-8. 10.12860\/jnp.2014.02","journal-title":"J Nephropathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010668","article-title":"Catastrophic antiphospholipid syndrome","volume":"25","author":"Bitsadze V","year":"2024","unstructured":"Bitsadze V, Yakubova F, Khizroeva J, et al.. Catastrophic antiphospholipid syndrome. Int J Mol Sci. 2024, 25:10.3390\/ijms25010668","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.06.005","article-title":"The catastrophic antiphospholipid (Asherson's) syndrome","volume":"6","author":"Asherson RA","year":"2006","unstructured":"Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome. Autoimmun Rev. 2006, 6:64-7. 10.1016\/j.autrev.2006.06.005","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"13","author":"Jacobs L","year":"2024","unstructured":"Jacobs L, Wauters N, Lablad Y, Morelle J, Taghavi M. Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria. Antibodies (Basel). 2024, 13:10.3390\/antib13010021","journal-title":"Antibodies (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000172074.53583.ea","article-title":"Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?","volume":"84","author":"G\u00f3mez-Puerta JA","year":"2005","unstructured":"G\u00f3mez-Puerta JA, Mart\u00edn H, Amigo MC, et al.. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?. Medicine (Baltimore). 2005, 84:225-30. 10.1097\/01.md.0000172074.53583.ea","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. bmj","volume":"27","author":"Knight JS","year":"2023","unstructured":"Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. bmj. 2023, 27:380. 10.1136\/bmj-2021-069717"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.530","article-title":"Long term outcome of catastrophic antiphospholipid syndrome survivors","volume":"62","author":"Erkan D","year":"2003","unstructured":"Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, Lockshin MD. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003, 62:530-3. 10.1136\/ard.62.6.530","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20910855","article-title":"An update on the management of antiphospholipid syndrome","volume":"12","author":"Rodziewicz M","year":"2020","unstructured":"Rodziewicz M, D'Cruz DP. An update on the management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis. 2020, 12:10.1177\/1759720X20910855","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli S","year":"2006","unstructured":"Bucciarelli S, Espinosa G, Cervera R, et al.. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006, 54:2568-76. 10.1002\/art.22018","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.007245","article-title":"Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies","volume":"63","author":"Espinosa G","year":"2004","unstructured":"Espinosa G, Bucciarelli S, Cervera R, et al.. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004, 63:730-6. 10.1136\/ard.2003.007245","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"Sciascia S","year":"2015","unstructured":"Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015, 74:2028-33. 10.1136\/annrheumdis-2014-205663","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2005.10.002","article-title":"Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome","volume":"210","author":"Asherson RA","year":"2005","unstructured":"Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology. 2005, 210:727-33. 10.1016\/j.imbio.2005.10.002","journal-title":"Immunobiology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1201\/b17855","article-title":"Recurrent pregnancy loss: causes, controversies, and treatment, second edition","year":"2014","unstructured":"Recurrent pregnancy loss. causes, controversies, and treatment, second edition. HJ Carp (ed): CRC Press, Boca Raton; 2014. 10.1201\/b17855"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/path.1491","article-title":"Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome","volume":"202","author":"Bhatia M","year":"2004","unstructured":"Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 2004, 202:145-56. 10.1002\/path.1491","journal-title":"J Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni PL","year":"2011","unstructured":"Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011, 7:330-9. 10.1038\/nrrheum.2011.52","journal-title":"Nat Rev Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos B","year":"2013","unstructured":"Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013, 368:1033-44. 10.1056\/NEJMra1112830","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361519","article-title":"Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome","volume":"15","author":"Feng W","year":"2024","unstructured":"Feng W, Qiao J, Tan Y, et al.. Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome. Front Immunol. 2024, 15:1361519. 10.3389\/fimmu.2024.1361519","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000200","article-title":"Update on the pathogenesis and treatment of the antiphospholipid syndrome","volume":"27","author":"Chighizola CB","year":"2015","unstructured":"Chighizola CB, Raschi E, Borghi MO, Meroni PL. Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol. 2015, 27:476-82. 10.1097\/BOR.0000000000000200","journal-title":"Curr Opin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"Carmi O","year":"2017","unstructured":"Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017, 10:365-74. 10.1080\/17474086.2017.1300522","journal-title":"Expert Rev Hematol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2349","article-title":"Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies","volume":"101","author":"Raschi E","year":"2003","unstructured":"Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, Meroni PL. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003, 101:3495-500. 10.1182\/blood-2002-08-2349","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.10.001","article-title":"Antiphospholipid antibodies, antiphospholipid syndrome and infections","volume":"7","author":"S\u00e8ne D","year":"2008","unstructured":"S\u00e8ne D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008, 7:272-7. 10.1016\/j.autrev.2007.10.001","journal-title":"Autoimmun Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-022-01228-0","article-title":"Neurologic manifestations of catastrophic antiphospholipid syndrome","volume":"22","author":"Mustafa R","year":"2022","unstructured":"Mustafa R. Neurologic manifestations of catastrophic antiphospholipid syndrome. Current Neurology and Neuroscience Reports. 2022, 22:589-600. 10.1007\/s11910-022-01228-0","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/nature01326","article-title":"The immunopathogenesis of sepsis","volume":"420","author":"Cohen J","year":"2002","unstructured":"Cohen J. The immunopathogenesis of sepsis. Nature. 2002, 420:885-91. 10.1038\/nature01326","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.06.006","article-title":"Historical perspective on the current renaissance for hematopoietic stem cell gene therapy","volume":"31","author":"Kohn DB","year":"2017","unstructured":"Kohn DB. Historical perspective on the current renaissance for hematopoietic stem cell gene therapy. Hematol Oncol Clin North Am. 2017, 31:721-35. 10.1016\/j.hoc.2017.06.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(98)00061-8","article-title":"Thrombotic storm: when thrombosis begets thrombosis","volume":"104","author":"Kitchens CS","year":"1998","unstructured":"Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med. 1998, 104:381-5. 10.1016\/s0002-9343(98)00061-8","journal-title":"Am J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead603","article-title":"Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?","volume":"63","author":"Raschi E","year":"2024","unstructured":"Raschi E, Borghi MO, Tedesco F, Meroni PL. Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?. Rheumatology (Oxford). 2024, 63:SI4-13. 10.1093\/rheumatology\/kead603","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2016","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016, 15:1120-4. 10.1016\/j.autrev.2016.09.010","journal-title":"Autoimmun Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \"CAPS Registry\"","volume":"21","author":"L\u00f3pez-Benjume B","year":"2022","unstructured":"L\u00f3pez-Benjume B, Rodr\u00edguez-Pint\u00f3 I, Amigo MC, Erkan D, Shoenfeld Y, Cervera R, Espinosa G. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \"CAPS Registry\". Autoimmun Rev. 2022, 21:103055. 10.1016\/j.autrev.2022.103055","journal-title":"Autoimmun Rev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi S","year":"2020","unstructured":"Chaturvedi S, Braunstein EM, Yuan X, et al.. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020, 135:239-51. 10.1182\/blood.2019003863","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2024.02.011","article-title":"Catastrophic antiphospholipid syndrome: lessons from the \"CAPS Registry\"","volume":"163","author":"Rodriguez-Pint\u00f3 I","year":"2024","unstructured":"Rodriguez-Pint\u00f3 I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: lessons from the \"CAPS Registry\". Med Clin (Barc). 2024, 163:S31-5. 10.1016\/j.medcli.2024.02.011","journal-title":"Med Clin (Barc)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.09.001","article-title":"Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark","volume":"136","author":"Lund JL","year":"2015","unstructured":"Lund JL, \u00d8stg\u00e5rd LS, Prandoni P, S\u00f8rensen HT, de Nully Brown P. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thromb Res. 2015, 136:917-23. 10.1016\/j.thromres.2015.09.001","journal-title":"Thromb Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-10-52","article-title":"Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays","volume":"10","author":"de Jager W","year":"2009","unstructured":"de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009, 10:52. 10.1186\/1471-2172-10-52","journal-title":"BMC Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera R","year":"2018","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun. 2018, 92:1-11. 10.1016\/j.jaut.2018.05.007","journal-title":"J Autoimmun"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1160\/TH06-08-0429","article-title":"Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding","volume":"97","author":"Charbonneau S","year":"2007","unstructured":"Charbonneau S, Girard F, Boudreault D, Ruel M, Blais N, Hardy JF. Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding. Thromb Haemost. 2007, 97:296-303.","journal-title":"Thromb Haemost"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.10.007","article-title":"The clinical spectrum of antiphospholipid syndrome","volume":"22","author":"Baker WF Jr","year":"2008","unstructured":"Baker WF Jr, Bick RL. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am. 2008, 22:33-52. 10.1016\/j.hoc.2007.10.007","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13726","article-title":"What the neighbors say","volume":"15","year":"2017","unstructured":"What the neighbors say. J Thromb Haemost. 2017, 15.1050. 10.1111\/jth.13726","journal-title":"J Thromb Haemost"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.5221","article-title":"Cutaneous involvement in catastrophic antiphospholipid syndrome in a multicenter cohort of 65 patients","volume":"159","author":"Dupr\u00e9 A","year":"2023","unstructured":"Dupr\u00e9 A, Morel N, Yelnik C, et al.. Cutaneous involvement in catastrophic antiphospholipid syndrome in a multicenter cohort of 65 patients. JAMA Dermatol. 2023, 159:62-7. 10.1001\/jamadermatol.2022.5221","journal-title":"JAMA Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2021.07.002","article-title":"Catastrophic antiphospholipid syndrome during pregnancy","volume":"264","author":"Fuentes Carrasco M","year":"2021","unstructured":"Fuentes Carrasco M, Mayoral Triana A, Crist\u00f3bal Garc\u00eda IC, P\u00e9rez P\u00e9rez N, Izquierdo M\u00e9ndez N, Soler Ruiz P, Gonz\u00e1lez Gonz\u00e1lez V. Catastrophic antiphospholipid syndrome during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021, 264:21-4. 10.1016\/j.ejogrb.2021.07.002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi153","article-title":"Thrombotic microangiopathy in United States long-term dialysis patients","volume":"21","author":"Perkins RM","year":"2006","unstructured":"Perkins RM, Reynolds JC, Ahuja TS, et al.. Thrombotic microangiopathy in United States long-term dialysis patients. Nephrol Dial Transplant. 2006, 21:191-6. 10.1093\/ndt\/gfi153","journal-title":"Nephrol Dial Transplant"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia F","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al.. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014, 66:3160-9. 10.1002\/art.38802","journal-title":"Arthritis Rheumatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14204","article-title":"In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications","author":"Canis K","year":"2018","unstructured":"Canis K, Anzengruber J, Garenaux E, et al.. In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications. J Thromb Haemost. 2018, 10.1111\/jth.14204","journal-title":"J Thromb Haemost"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236984","article-title":"Anticoagulant therapy in patients with antiphospholipid syndrome","volume":"11","author":"Capecchi M","year":"2022","unstructured":"Capecchi M, Abbattista M, Ciavarella A, Uhr M, Novembrino C, Martinelli I. Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med. 2022, 11:10.3390\/jcm11236984","journal-title":"J Clin Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"30","author":"Lim W","year":"2016","unstructured":"Lim W. Antiphospholipid syndrome. Hematol Oncol Clin North Am. 2016, 30:473-86. 10.1182\/asheducation-2013.1.675","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06062","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms J","year":"2020","unstructured":"Helms J, Tacquard C, Severac F, et al.. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020, 46:1089-98. 10.1007\/s00134-020-06062","journal-title":"Intensive Care Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/096120339400300206","article-title":"Antiphospholipid syndrome: clinical and therapeutic aspects","volume":"3","author":"Vlachoyiannopoulos PG","year":"1994","unstructured":"Vlachoyiannopoulos PG, Tsiakou E, Chalevelakis G, Raptis SA, Moutsopoulos HM. Antiphospholipid syndrome: clinical and therapeutic aspects. Lupus. 1994, 3:91-6. 10.1177\/096120339400300206","journal-title":"Lupus"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19635","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","author":"Arachchillage DJ","year":"2024","unstructured":"Arachchillage DJ, Platton S, Hickey K, et al.. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2024, 10.1111\/bjh.19635","journal-title":"Br J Haematol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.12.002","article-title":"CXCL10 and autoimmune diseases","volume":"8","author":"Lee EY","year":"2009","unstructured":"Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009, 8:379-83. 10.1016\/j.autrev.2008.12.002","journal-title":"Autoimmun Rev"},{"key":"ref52","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar UD","year":"2007","unstructured":"Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007, 34:346-52.","journal-title":"J Rheumatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan D","year":"2014","unstructured":"Erkan D, Willis R, Murthy VL, et al.. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014, 73:1176-80. 10.1136\/annrheumdis-2013-203622","journal-title":"Ann Rheum Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307085","article-title":"Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature","volume":"17","author":"Erre GL","year":"2008","unstructured":"Erre GL, Pardini S, Faedda R, et al.. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008, 17:50-5. 10.1177\/0961203307085","journal-title":"Lupus"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman H","year":"2013","unstructured":"Berman H, Rodr\u00edguez-Pint\u00f3 I, Cervera R, et al.. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013, 12:1085-90. 10.1016\/j.autrev.2013.05.004","journal-title":"Autoimmun Rev"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145145","article-title":"An update on the biologics for the treatment of antiphospholipid syndrome","volume":"14","author":"Yun Z","year":"2023","unstructured":"Yun Z, Duan L, Liu X, Cai Q, Li C. An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol. 2023, 14:1145145. 10.3389\/fimmu.2023.1145145","journal-title":"Front Immunol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/art.34440","article-title":"Brief report: Induction of sustained remission in severe and refractory nonrenal systemic lupus erythematosus by eculizumab: A pilot study","volume":"64","author":"Shapira I","year":"2012","unstructured":"Shapira I, Andrade D, Allen SL, Salmon JE, Belmont HM. Brief report: Induction of sustained remission in severe and refractory nonrenal systemic lupus erythematosus by eculizumab: A pilot study. Arthritis Rheumatol. 2012, 64:4040-7. 10.1002\/art.34440","journal-title":"Arthritis Rheumatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan M","year":"2014","unstructured":"Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014, 2014:704371. 10.1155\/2014\/704371","journal-title":"Case Rep Hematol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi G","year":"2003","unstructured":"Girardi G, Berman J, Redecha P, et al.. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003, 112:1644-54. 10.1172\/JCI18817","journal-title":"J Clin Invest"},{"key":"ref60","article-title":"Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator","volume":"29","author":"Burcoglu-O'Ral A","year":"2002","unstructured":"Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol. 2002, 29:2006-11.","journal-title":"J Rheumatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037671","article-title":"The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients","volume":"65","author":"Bucciarelli S","year":"2006","unstructured":"Bucciarelli S, Espinosa G, Asherson RA, et al.. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Ann Rheum Dis. 2006, 65:81-6. 10.1136\/ard.2005.037671","journal-title":"Ann Rheum Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1900733","article-title":"Antiphospholipid syndrome: the need for new international classification criteria","volume":"17","author":"El Hasbani G","year":"2021","unstructured":"El Hasbani G, Taher AT, Sciascia S, Uthman I. Antiphospholipid syndrome: the need for new international classification criteria. Expert Rev Clin Immunol. 2021, 17:385-94. 10.1080\/1744666X.2021.1900733","journal-title":"Expert Rev Clin Immunol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz NM","year":"2016","unstructured":"Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016, 28:218-27. 10.1097\/BOR.0000000000000269","journal-title":"Curr Opin Rheumatol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.001","article-title":"Relapsing catastrophic antiphospholipid syndrome: report of three cases","volume":"37","author":"Asherson RA","year":"2008","unstructured":"Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, Cervera R. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum. 2008, 37:366-72. 10.1016\/j.semarthrit.2007.08.001","journal-title":"Semin Arthritis Rheum"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya M","year":"2023","unstructured":"Barbhaiya M, Zuily S, Naden R, et al.. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023, 75:1687-702. 10.1002\/art.42624","journal-title":"Arthritis Rheumatol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025759","article-title":"Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome","volume":"64","author":"Cervera R","year":"2005","unstructured":"Cervera R, Font J, G\u00f3mez-Puerta JA, et al.. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005, 64:1205-9. 10.1136\/ard.2004.025759","journal-title":"Ann Rheum Dis"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0034-x","article-title":"Antiphospholipid antibodies in response to infection","volume":"9","author":"Avcin T","year":"2007","unstructured":"Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007, 9:212-8. 10.1007\/s11926-007-0034-x","journal-title":"Curr Rheumatol Rep"},{"key":"ref68","article-title":"Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus","volume":"16","author":"Drenkard C","year":"1989","unstructured":"Drenkard C, S\u00e1nchez-Guerrero J, Alarc\u00f3n-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol. 1989, 16:614-7.","journal-title":"J Rheumatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti MG","year":"2019","unstructured":"Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, De Cata A. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019, 19:281-8. 10.1007\/s10238-019-00565-8","journal-title":"Clin Exp Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109727","article-title":"Assessing disease activity and damage in antiphospholipid syndrome","volume":"255","author":"Andrade D","year":"2023","unstructured":"Andrade D, Tektonidou MG. Assessing disease activity and damage in antiphospholipid syndrome. Clin Immunol. 2023, 255:109727. 10.1016\/j.clim.2023.109727","journal-title":"Clin Immunol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106492","article-title":"Risk factors for ischemic antiphospholipid syndrome: a case-control study","volume":"202","author":"Matus-Mayorga R","year":"2021","unstructured":"Matus-Mayorga R, Barrera-Vargas A, Rull-Gabayet M, et al.. Risk factors for ischemic antiphospholipid syndrome: a case-control study. Clin Neurol Neurosurg. 2021, 202:106492. 10.1016\/j.clineuro.2021.106492","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/284806-catastrophic-antiphospholipid-syndrome-a-review-of-current-evidence-and-future-management-practices","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:08:18Z","timestamp":1726747698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/284806-catastrophic-antiphospholipid-syndrome-a-review-of-current-evidence-and-future-management-practices"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":71,"URL":"https:\/\/doi.org\/10.7759\/cureus.69730","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}